EXTON,
Pa., Jan. 22, 2025 /PRNewswire/ -- West
Pharmaceutical Services, Inc. (NYSE: WST), a global leader in
innovative solutions for injectable drug administration, today
announced the introduction of Daikyo PLASCAP® Ready-to-Use
Validated (RUV) closures in a new nested format available in
multiple configurations at this year's Pharmapack event in
Paris, France. This marks
West's latest product offering supporting the needs of advanced
therapies, one of the fastest growing areas, driven by continued
innovation in cell and gene therapy treatments.
The PLASCAP® closure is a metal-free polypropylene cap
with an integrated stopper. This one-step press-fit solution for
vial closure is offered in ready-to-use, validated formats
compatible with vials with 13mm and 20 mm crowns. The new 6x8
nested tub configuration supports the West 10ml nested CZ vials as
well as selected nested vials with a 20mm crown.
"West has been a leader in pharmaceutical packaging for over 100
years, and our containment solutions are used for the majority of
gene and viral therapies in the market," said Stacey Vaughan, Vice President of Strategic
Portfolio Management. "The introduction of this new nested format
for our PLASCAP closures addresses the complex challenges of
containment for advanced therapy molecules while meeting increasing
regulatory requirements of the market."
For more information about PLASCAP® click here.
To learn more about West, please visit our website:
www.westpharma.com.
Forward-Looking Statements
Certain forward-looking statements are included in this press
release. They use words such as "supporting," "addresses,"
"meeting," and other similar terminology. These statements reflect
management's current expectations regarding future events and
operating performance and speak only as of the date of this
release. There is no certainty that actual results will be achieved
in-line with current expectations. Specifically, there is no
certainty that West's introduction of the PLASCAP® RUV closures in
a new nested format will achieve any particular result. These
forward-looking statements involve a number of risks and
uncertainties. Various factors could cause the actual results to
differ materially from those expressed in, or underlying, these
forward-looking statements, such as customer decisions to move
forward with new products and product categories; average
profitability, or mix, of the products offered for sale; dependence
on third party suppliers and partners; interruptions or weaknesses
in the supply chain; fluctuations in currency exchange; and the
ability to meet development milestones with key customers. These
important factors are not all inclusive. For a description of
certain additional factors that could cause West's future results
to differ from those expressed in any such forward-looking
statements, see Item 1A, entitled "Risk Factors," in West's Annual
Report on Form 10-K for the year ended December 31, 2023. Except as required by law or
regulation, West undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading provider of
innovative, high-quality injectable solutions and services. As a
trusted partner to established and emerging drug developers, West
helps ensure the safe, effective containment and delivery of
life-saving and life-enhancing medicines for patients. With over
10,000 team members across 50 sites worldwide, West helps support
our customers by delivering approximately 43 billion components and
devices each year.
Headquartered in Exton,
Pennsylvania, West in its fiscal year 2023 generated
$2.95 billion in net sales. West is
traded on the New York Stock Exchange (NYSE: WST) and is included
on the Standard & Poor's 500 index. For more information, visit
www.westpharma.com.
Crystal Zenith and PLASCAP are registered trademarks of
Daikyo Seiko, Ltd. and are used under license.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/west-introduces-daikyo-plascap-ruv-closures-in-new-nested-format-at-pharmapack-302356582.html
SOURCE West Pharmaceutical Services, Inc.
